Catalyst Pharmaceuticals (CPRX) Expected to Post Earnings on Wednesday

Posted by George Bondi on Aug 3rd, 2026

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) is anticipated to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.48 per share and revenue of $155.7920 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $31.49 on Monday. The firm has a market capitalization of $3.86 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74. The business has a 50 day simple moving average of $31.41 and a two-hundred day simple moving average of $27.63. Catalyst Pharmaceuticals has a 1 year low of $19.05 and a 1 year high of $32.56.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada increased its stake in shares of Catalyst Pharmaceuticals by 39.1% during the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock valued at $5,177,000 after buying an additional 60,040 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Catalyst Pharmaceuticals by 5.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock worth $1,749,000 after acquiring an additional 3,800 shares during the period. Goldman Sachs Group Inc. lifted its stake in Catalyst Pharmaceuticals by 11.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after acquiring an additional 333,100 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Catalyst Pharmaceuticals by 99.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock worth $12,763,000 after acquiring an additional 262,392 shares in the last quarter. Finally, Intech Investment Management LLC grew its holdings in Catalyst Pharmaceuticals by 6.5% during the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock worth $1,700,000 after acquiring an additional 4,261 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $35.00 to $31.50 in a report on Thursday, May 28th. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Finally, Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Get Our Latest Stock Report on Catalyst Pharmaceuticals

About Catalyst Pharmaceuticals

(Get Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).

Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.